1-7 of 7
Michael Klichinsky, PharmD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, J. Joseph Melenhorst, PhD, Mariusz A Wasik, MD, Simon F. Lacey, PhD, Carl H June, MD, Saar I Gill, MBBS, PhD
Journal: Blood
Blood (2016) 128 (22): 2159.
https://doi.org/10.1182/blood.V128.22.2159.2159
Published: 2016
Journal Articles

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, Craig Soderquist, MD, Adam Bagg, MD, Reshma Singh, PhD, Celeste Richardson, PhD, Regina M Young, PhD, Carl H June, MD, Saar I. Gill, MD PhD
Journal: Blood
Blood (2016) 128 (22): 766.
https://doi.org/10.1182/blood.V128.22.766.766
Published: 2016
Journal Articles

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Miriam Y Kim, MD, Michael Klichinsky, PharmD, Fang Chen, PhD, Natalka Kengle, Simon Francis Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD
Journal: Blood
Blood (2016) 128 (22): 652.
https://doi.org/10.1182/blood.V128.22.652.652
Published: 2016
Journal Articles

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Miriam Y Kim, MD, Saad S Kenderian, MD, Daniel Schreeder, MD PhD, Michael Klichinsky, PharmD, Miroslaw Kozlowski, PhD, Olga Shestova, PhD, Marco Ruella, MD, Saar I Gill, MBBS, PhD
Journal: Blood
Blood (2016) 128 (22): 1000.
https://doi.org/10.1182/blood.V128.22.1000.1000
Published: 2016
Journal Articles

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Marco Ruella, MD, Michael Klichinsky, PharmD, Saad S Kenderian, MD, Olga Shestova, PhD, Amy Ziober, Michael D Feldman, MD, Mariusz A Wasik, MD, Carl H June, MD, Saar I Gill, MBBS, PhD
Journal: Blood
Blood (2016) 128 (22): 43.
https://doi.org/10.1182/blood.V128.22.43.43
Published: 2016
Journal Articles

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Joseph A. Fraietta, PhD, Sohail Qayyum, MD, Qian Zhang, MD PhD, Marcela V. Maus, MDPhD, Xiaobin Liu, PhD, Selene Nunez-Cruz, PhD, Michael Klichinsky, PharmD, Omkar Uday Kawalekar, MS, BS, Michael C. Milone, MD PhD, Simon F. Lacey, PhD BSc, Anthony Mato, MD, Stephen J. Schuster, MD, Michael Kalos, PhD, Carl H. June, MD, Saar I Gill, MBBS, PhD, Mariusz A. Wasik, MD
Journal: Blood
Blood (2015) 126 (23): 704.
https://doi.org/10.1182/blood.V126.23.704.704
Published: 2015
Journal Articles

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, David L Porter, MD, Carl H. June, MD, Saar I Gill, MBBS, PhD
Journal: Blood
Blood (2015) 126 (23): 852.
https://doi.org/10.1182/blood.V126.23.852.852
Published: 2015